WO2020151229A1 - 一种蛋白靶向降解嵌合分子、制备方法及应用 - Google Patents

一种蛋白靶向降解嵌合分子、制备方法及应用 Download PDF

Info

Publication number
WO2020151229A1
WO2020151229A1 PCT/CN2019/104300 CN2019104300W WO2020151229A1 WO 2020151229 A1 WO2020151229 A1 WO 2020151229A1 CN 2019104300 W CN2019104300 W CN 2019104300W WO 2020151229 A1 WO2020151229 A1 WO 2020151229A1
Authority
WO
WIPO (PCT)
Prior art keywords
abl
bcr
compound
protein
degradation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/CN2019/104300
Other languages
English (en)
French (fr)
Inventor
尤启冬
姜正羽
汪艳
金雨辉
陆朦辰
徐晓莉
郭小可
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
China Pharmaceutical University
Original Assignee
China Pharmaceutical University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by China Pharmaceutical University filed Critical China Pharmaceutical University
Priority to US15/734,960 priority Critical patent/US11504385B2/en
Publication of WO2020151229A1 publication Critical patent/WO2020151229A1/zh
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/655—Azo (—N=N—), diazo (=N2), azoxy (>N—O—N< or N(=O)—N<), azido (—N3) or diazoamino (—N=N—N<) compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0023—Aggression treatment or altering
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545—Heterocyclic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings

Definitions

  • the invention belongs to the field of chemistry, and specifically relates to a protein targeted degradation chimeric molecule, a preparation method and an application.
  • Targeted protein degradation chimera is an emerging technology that uses the ubiquitin-proteasome system to induce the ubiquitination and degradation of a certain protein by recruiting the E3 ubiquitin ligase of a specific protein, thereby regulating the protein concentration. Compared with traditional small molecule inhibitors, PROTAC technology can more effectively act on non-drugged proteins.
  • BCR-ABL fusion protein is universally present in chronic myeloid leukemia (CML) cases.
  • ABL and BCR-ABL proteins are also one of the earliest targets used in PROTAC research.
  • the CREWS research group took the lead in using the PROTAC strategy to successfully down-regulate the expression level of the BCR-ABL fusion protein in K562 leukemia cells.
  • the PROTAC small molecule they designed can simultaneously degrade BCR-ABL and ABL proteins at low concentrations.
  • ABL is involved in the response of growth factors and cytokines, and is also related to multiple signaling pathways such as cell adhesion, DNA damage, and oxidative stress.
  • ABL is activated to stimulate cell proliferation or differentiation, survival or death, withdrawal or migration. Knockout of ABL gene can cause abnormal cell cycle function.
  • the present invention aims to overcome the shortcomings of the prior art and provide an adjustable PROTAC molecule that can reversibly, rapidly and easily use the PROTAC strategy to down-regulate the expression levels of BCR-ABL and ABL proteins in K562 leukemia cells; at the same time, the present invention also The aim is to provide a feasible method for the synthesis and preparation of the PROTAC molecule.
  • a chimeric molecule targeted for protein degradation with the following chemical structure:
  • n is any natural number from 1 to 5.
  • n 3.
  • n is any natural number from 1 to 5.
  • FIG. 1 Schematic diagram of the photoisomerization of compound 4C
  • Figure 2 The chemical structures of compounds 2C to 6C and the immunoblotting detection image for the degradation activity of ABL and BCR-ABL in the BCR-ABL and CRBN positive K562 cell lines;
  • Figure 4 A) determination of the anti-cell proliferation activity of compound 4C-trans on K562 cell line; B) determination of cell viability of compound 4C-trans on A549, HCT116, MCF-7 and K562 cell lines; C) compound 4C at a concentration of 250 nM -Trans immunoblotting time-effect experiment; D) 24 hours after administration, compound 4C-trans immunoblotting dose-effect experiment;
  • Figure 5 A) Immunoblotting of compound 4C-trans after 24 hours of incubation-dose effect experiment B) Western blotting of compound 4C-trans at a concentration of 250 nM-time effect experiment; C) after 24 hours of incubation, immunization of compound 4C-cis Blotting-dose-response experiment; D) Western blotting of compound 4C-cis at a concentration of 250 nM-aging experiment;
  • FIG 6 shows the changes of BCR-ABL protein concentration over time in K562 cells treated with compound 4C-trans in the dark (VIS group) and ultraviolet light (irradiated once every 4 hours);
  • Figure 7 shows the effect of different concentrations of compound 4C-trans on ABL gene expression
  • Figure 8 is a curve of the effect of compound 4C-trans at a concentration of 500 nM on ABL gene expression over time.
  • Figure 2D shows the dose-effect relationship of 3C compound on ABL and BCR-ABL protein degradation in K562 cell line
  • Figure 2E shows the dose-effect relationship of 4C compound on ABL and BCR-ABL protein degradation in K562 cell line
  • Figure 2F is 5C The dose-effect relationship of the compound on the degradation of ABL and BCR-ABL protein in K562 cell line
  • Figure 2G shows the dose-effect relationship of the degradation of ABL and BCR-ABL protein in K562 cell line by the 6C compound.
  • the absorbance-time graph at 361nm shows that the compound is almost completely converted to the cis configuration after 1 hour of ultraviolet irradiation ( Figure 3B).
  • Compound 4C in the cis configuration gradually converted to the trans configuration after white light irradiation ( Figure 3C).
  • the cis configuration undergoes self-heating relaxation under dark conditions to transform into the trans configuration, and T1/2 is about 10 hours at 25°C.
  • the researchers further evaluated the cellular activity of compound 4C.
  • the half inhibitory concentration (IC50) of compound 4C was 68nM ( Figure 4A); in the cell viability test, the half effective concentration (EC50) of compound 4C was 28nM ( Figure 4B); in addition, the compound 4C 4C basically does not affect non-BCR-ABL dependent tumor cell lines, such as A549, HCT116, HEK293T and MCF-7 breast cancer ( Figure 4B). It can be seen that compound 4C has good selectivity for the BCR-ABL-dependent K562 cell line.
  • the operation method of anti-K562 cell proliferation activity test is as follows:
  • Cytotoxicity (%) [A(adding medicine)-A(blank)]/[A(0adding)-A(blank)] ⁇ 100, where:
  • the dose-effect experiment showed that compared with the control group, the mRNA level of the ABL gene in K562 cells treated with different concentrations of compound 4C for 36 hours did not change significantly; the aging experiment showed that K562 cells were incubated with 500 nM compound 4C for 48 hours No significant decrease in ABL gene mRNA level was observed in.
  • RODI reverse osmosis deionized water
  • 1*PBS Add 50ml 20*PBS to 950ml dH2O and mix.
  • 1*TBS Add 100ml 10*TBS to 900ml dH2O and mix.
  • 1* running buffer add 100ml 10* running buffer to 900ml dH2O and mix.
  • 1*transfer buffer add 100ml 10*transfer buffer to 100ml methanol + 800ml dH2O and mix.
  • 1*TBST Add 100ml 10X TBST to 900ml dH2O and mix.
  • Blocking buffer 1*TBST containing 5% w/v skimmed milk powder
  • Washing buffer 1*BST.
  • Primary antibody dilution buffer 1*TBST containing 5% skimmed milk powder; to prepare 20ml, add 1.0g skimmed milk powder to 20ml 1*TBST, and then mix thoroughly.
  • HRP-conjugated secondary antibody Anti-rabbit IgG, HRP-linked Antibody (#7074).
  • Detection reagent SignalFire TM ECL Reagent (#6883).
  • the coding sequence was selected, and GenScript Biotechnology Co., Ltd. was commissioned to design and synthesize primers.
  • the sequence is as follows:
  • the K 562 cell resuspension collected in a 1.5 mL centrifuge tube was centrifuged briefly, the culture supernatant was removed, an appropriate amount of Trizol reagent was added and the cells were lysed by pipetting repeatedly, and the cells were allowed to stand at room temperature for 5 minutes; add 0.2 times the volume of the above lysis solution After vortexing for 15 seconds, let stand at room temperature for 3 minutes; centrifuge at 12000 rpm and 4°C for 15 minutes, carefully remove the centrifuge tube from the centrifuge, transfer the upper water phase to a new centrifuge tube; add an equal volume of isopropanol, mix After homogenization, let stand at room temperature for 10 min; centrifuge at 12000 rpm and 4°C for 15 min.
  • RNA precipitates at the bottom of the test tube carefully discard the supernatant, add 1 mL of 75% ethanol (0.1%, prepared with DEPC water), and invert evenly; 10 min; Centrifuge at 12000rpm and 4°C for 15min.
  • the mixed solution should be dry-bathed at 70°C for 3 minutes. After taking it out, it should be bathed in ice water until the temperature inside and outside the tube is the same, and then 0.5ul of reverse transcriptase should be added and bathed at 37°C for 60 minutes. After taking it out, dry it in a dry bath at 95°C for 3 minutes to obtain the final reverse transcription solution, which is the cDNA solution, which is stored at -80°C for later use.
  • the researchers treated K562 cells with compound 4C-trans for 24 hours, then moved these cells to fresh medium and divided them into two groups: one group was placed in a dark room (VIS group), and the other group was placed in a dark room (VIS group). After incubation for 0, 4, 8, 12, 16, and 24 hours, they were irradiated with ultraviolet light to simulate the photoisomerization process (UV group).
  • UV group the photoisomerization process
  • the results showed that in the dark group, the BCR-ABL fusion protein remained at a low level and ABL almost disappeared (Figure 6-VIS), while in the UV group, the levels of ABL and BCR-ABL increased over time (Figure 6-UV) .
  • the final concentration of 100nM compound 4C-trans was added to K562 cells and incubated at 37°C for 24 hours; the medium was washed off and washed twice with 1*PBS, then the cells were transferred to fresh 1640 medium (10% FBS, 1*gu Aminoamide) cultured and divided into two groups: one group was placed in a dark room, the other group was irradiated with UV-C light for 30 minutes every 4 hours; cells were collected after transfer and incubation for 0, 4, 8, 16, and 24 hours. Cell post-processing is the same as that of immunoblotting.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

公开了一种蛋白靶向降解嵌合分子、制备方法及应用。提供的蛋白靶向降解嵌合分子可不同程度地抑制BCR-ABL和/或CRBN阳性的白血病K562细胞中BCR-ABL和/或CRBN蛋白的表达，因而可以用于制备治疗BCR-ABL和/或CRBN阳性的白血病的药物，其中，n＝3的蛋白靶向降解嵌合分子具有优异的光致异构化活性，可以用于制备光照调控降解BCR-ABL和/或CRBN蛋白的试剂或药物；还提供了一种合成该系列蛋白靶向降解嵌合分子的方法。

Description

一种蛋白靶向降解嵌合分子、制备方法及应用 技术领域
本发明属于化学领域，具体涉及一种蛋白靶向降解嵌合分子、制备方法及应用。
背景技术
蛋白靶向降解嵌合(PROTAC)是一项新兴技术，该技术能够利用泛素-蛋白酶体系统，通过招募特定蛋白的E3泛素连接酶诱导某一蛋白的泛素化降解，进而调节该蛋白的浓度。相比于传统的小分子抑制剂，PROTAC技术能够更有效的作用于那些非成药性蛋白。
临床研究表明，BCR-ABL融合蛋白普遍存在于慢性粒细胞白血病(CML)病例中。同时，ABL和BCR-ABL蛋白也是最早用于PROTAC研究的靶标之一。2016年，CREWS课题组率先利用PROTAC策略成功下调了K562白血病细胞中BCR-ABL融合蛋白的表达水平，他们设计的PROTAC小分子能够在低浓度下同时降解BCR-ABL和ABL蛋白。
然而，相关研究表明，ABL参与生长因子与细胞因子应答，同时与细胞粘附，DNA损伤，氧化应激等多条信号通路有关。ABL被激活以刺激细胞增殖或分化，存活或死亡，撤回或迁移，ABL基因的敲除会导致细胞周期功能异常。
但是，如何调控PROTAC分子才能避免ABL蛋白的过度降解呢？这就亟需解决一个技术难题，即如何调控PROTAC分子介导的目标蛋白降解过程。
发明内容
本发明旨在克服现有技术的不足，提供一种可调节的PROTAC分子，以可逆、迅速、简易地利用PROTAC策略下调K562白血病细胞中BCR-ABL和ABL蛋白的表达水平；同时，本发明还旨在提供一种合成制备该PROTAC分子的可行方法。
本发明上述目的通过如下技术方案实现：
一种蛋白靶向降解嵌合分子，化学结构式如下：
Figure PCTCN2019104300-appb-000001
其中，n为1～5中任一自然数。
优选地，n＝3。
上述蛋白靶向降解嵌合分子的合成方法，合成路线如下：
Figure PCTCN2019104300-appb-000002
其中，n为1～5中任一自然数。
上述蛋白靶向降解嵌合分子在制备治疗BCR-ABL和/或CRBN阳性的白血病的药物中的应用。
上述n＝3的蛋白靶向降解嵌合分子在制备光照调控降解BCR-ABL和/或CRBN蛋白的试剂或药物方面的应用。
有益效果：
本发明提供的蛋白靶向降解嵌合分子可不同程度地抑制BCR-ABL和/或CRBN阳性的白血病K562细胞中BCR-ABL和/或CRBN蛋白的表达，因而可以用于制备治疗BCR-ABL和/或CRBN阳性的白血病的药物，其中，n＝3的蛋白靶向降解嵌合分子具有优异的光致异构化活性，可以用于制备光照调控降解BCR-ABL和/或CRBN蛋白的试剂或药物；本发明还提供了一种合成该系列蛋白靶向降解嵌合分子的方法。
附图说明
图1：化合物4C的光致异构化示意图；
图2：化合物2C～6C的化学结构及对BCR-ABL和CRBN阳性K562细胞株中ABL和BCR-ABL蛋白降解活性的免疫印迹检测图；
图3：A)化合物4C-trans和cis构型的紫外-可见吸收光谱；B)化合物4C在周期实验，经UV-C照射后在λ＝361nm处检测吸光度；C)化合物4C-trans经紫外照射后紫外-可见吸收光谱随时间的变化；D)化合物4C-cis经白光照射后紫外-可见吸收光谱随时间的变化；
图4：A)化合物4C-trans对K562细胞系的抗细胞增殖活性测定；B)化合物4C-trans对A549、HCT116、MCF-7和K562细胞系的细胞活力测定；C)250nM浓度下化合物4C-trans免疫印迹的时效实验；D)给药24小时后，化合物4C-trans免疫印迹的量效实验；
图5：A)孵育24小时后，化合物4C-trans的免疫印迹-量效实验B)250nM浓度下化合物4C-trans的免疫印迹-时效实验；C)孵育24小时后，化合物4C-cis的免疫印迹-量效实验；D)250nM浓度下化合物4C-cis的免疫印迹-时效实验；
图6为化合物4C-trans处理过的K562细胞分别在黑暗(VIS组)和紫外光照条件(每4小时照射一次)下，BCR-ABL蛋白浓度随时间的变化；
图7为不同浓度化合物4C-trans对ABL基因表达的影响；
图8为500nM浓度的化合物4C-trans对ABL基因表达影响随时间变化曲线。
具体实施方式
下面结合附图和实施例具体介绍本发明实质性内容，但并不以此限定本发明的保护范围。实施例中，提到的室温或代表室温的缩写rt均指常温。
实施例1：PROTAC分子的合成和结构确证
合成路线图：
Figure PCTCN2019104300-appb-000003
(E)-4-((4-羟基苯基)二氮烯基)苯甲酸甲酯(3)
Figure PCTCN2019104300-appb-000004
将化合物2(11.54g，76.1mmol)溶于水(135ml)中，加入HCl(15.8ml，190mmol)，冰浴下冷却至5℃。向反应液中缓慢滴加预冷的亚硝酸钠(5.03g，79.8mmol)水溶液(35ml)，5℃下搅拌1小时。将苯酚(1)(7.52g，79.9mmol)，K 2CO 3(15.0g，108.5mmol)的水溶液(120ml)滴加到反应液中(10min滴完)，室温下搅拌3小时。用稀醋酸调节至pH＝4，有大量棕黄色固体析出。抽滤，滤饼依次用水和甲醇洗涤，得到棕色固体3(15.65g，80.3％)。
1H NMR(300MHz,DMSO-d6)δ10.57(s,1H),8.18–8.09(m,2H),7.96–7.80(m,4H),6.97(d,J＝8.4Hz,2H),3.89(s,3H).
Figure PCTCN2019104300-appb-000005
将化合物3(2.56g，10mmol)溶于N,N-二甲基甲酰胺(20ml)中，加入1-溴-2-氯乙烷(1.03ml，12mmol)和碳酸钾(4.14g，30mmol)，室温反应20h。向反应液中加入200mL水，大量棕黄色固体析出。抽滤，滤饼用10ml水洗涤3次，干燥后得到橘黄色固体4。
Figure PCTCN2019104300-appb-000006
(E)-4-((4-(2-氯乙氧基)苯基)二氮烯基)苯甲酸甲酯(4a)
1H NMR(300MHz,DMSO-d6)δ8.22–8.06(m,2H),7.98–7.81(m,4H),7.29–7.09(m,2H),4.38(t,J＝11.2Hz,2H),4.08–3.94(m,2H),3.90(s,3H).
Figure PCTCN2019104300-appb-000007
(E)-4-((4-(3-氯丙氧基)苯基)二氮烯基)苯甲酸甲酯(4b)
1H NMR(300MHz,Chloroform-d)δ8.24–8.12(m,2H),8.01–7.86(m,4H),7.09–6.97(m,2H),4.21(t,J＝5.8Hz,2H),3.95(s,3H),3.77(t,J＝6.2Hz,2H),2.28(p,J＝6.0Hz,2H).
Figure PCTCN2019104300-appb-000008
(E)-4-((4-(4-氯丁氧基)苯基)二氮烯基)苯甲酸甲酯(4c)
1H NMR(300MHz,Chloroform-d)δ8.17(d,J＝8.3Hz,2H),7.92(dd,J＝11.4,8.5Hz,4H),7.01(d,J＝8.5Hz,2H),4.09(d,J＝5.2Hz,2H),3.95(s,3H),3.63(d,J＝5.9Hz,2H),2.01(p,J＝2.9Hz,4H).
Figure PCTCN2019104300-appb-000009
(E)-4-((4-((5-氯戊基)氧基)苯基)二氮烯基)苯甲酸甲酯(4d)
1H NMR(300MHz,Chloroform-d)δ8.17(d,J＝8.4Hz,2H),7.99–7.85(m,4H),7.06–6.96(m,2H),4.07(t,J＝6.3Hz,2H),3.95(s,3H),3.59(t,J＝6.6Hz,2H),1.95–1.80(m,4H),1.66(ddt,J＝14.5,9.7,5.7Hz,2H).
Figure PCTCN2019104300-appb-000010
(E)-4-((4-((6-氯己基)氧基)苯基)二氮烯基)苯甲酸甲酯(4e)
1H NMR(300MHz,DMSO-d6)δ8.15(d,J＝8.0Hz,2H),7.93(d,J＝8.2Hz,4H),7.15(d,J＝8.4Hz,2H),4.17–4.05(m,2H),3.90(s,3H),3.65(s,2H),1.84-1.66(m,4H),1.56-1.38(m,4H).
Figure PCTCN2019104300-appb-000011
将化合物4(5mmol)溶于10ml四氢呋喃中，缓慢加入10ml氢氧化锂(600mg，25mmol)水溶液，室温下搅拌过夜。反应完成后在搅拌下向反应液中加入200mL水，用稀盐酸调节体系至pH＝2，有大量橙色固体析出。抽滤得粗品，滤饼用水洗涤3次，干燥后得到橙色固体5。
Figure PCTCN2019104300-appb-000012
(E)-4-((4-(2-氯乙氧基)苯基)二氮烯基)苯甲酸(5a)
1H NMR(300MHz,DMSO-d6)δ13.40–12.80(s,1H),8.32–8.10(m,2H),8.06–7.81(m,4H),7.29–7.09(m,2H),4.38(t,J＝10.8Hz,2H),4.12–3.92(m,2H).
Figure PCTCN2019104300-appb-000013
(E)-4-((4-(2-氯丙氧基)苯基)二氮烯基)苯甲酸(5b)
1H NMR(300MHz,DMSO-d6)δ8.06(d,J＝8.1Hz,2H),7.90(d,J＝8.5Hz,2H),7.78(d,J＝8.1Hz,2H),7.16(d,J＝8.5Hz,2H),5.76(s,2H),4.21(t,J＝6.1Hz,2H),3.82(t,J＝6.5Hz,2H),2.22(p,J＝6.4Hz,2H).
Figure PCTCN2019104300-appb-000014
(E)-4-((4-(2-氯丁氧基)苯基)二氮烯基)苯甲酸(5c)
1H NMR(300MHz,DMSO-d6)δ8.04(d,J＝8.0Hz,2H),7.90(d,J＝8.6Hz,2H),7.78(d,J＝8.1Hz,2H),7.14(d,J＝8.5Hz,2H),4.13(d,J＝5.2Hz,2H),1.97–1.77(m,4H).
Figure PCTCN2019104300-appb-000015
(E)-4-((4-(2-氯戊氧基)苯基)二氮烯基)苯甲酸(5d)
1H NMR(300MHz,DMSO-d6)δ8.09(d,J＝8.0Hz,2H),7.86(dd,J＝25.2,8.2Hz,4H),7.13(d,J＝8.5Hz,2H),4.10(t,J＝6.4Hz,2H),3.68(d,J＝13.2Hz,2H),1.79(dq,J＝12.5,5.6Hz,4H),1.57(q,J＝7.9Hz,2H).
Figure PCTCN2019104300-appb-000016
(E)-4-((4-(2-氯己氧基)苯基)二氮烯基)苯甲酸(5e)
1H NMR(300MHz,DMSO-d6)δ8.04(d,J＝7.9Hz,2H),7.88(d,J＝8.4Hz,2H),7.77(d,J＝7.9Hz,2H),7.12(d,J＝8.5Hz,2H),4.07(d,J＝6.6Hz,2H),3.64(t,J＝6.7Hz,2H),1.75(s,4H),1.46(s,4H).
Figure PCTCN2019104300-appb-000017
将化合物5(2.0mmol)溶于无水四氢呋喃(10ml)中，加入草酰氯(338ul，4.0mmol)，加1滴N，N-二甲基甲酰胺，室温下搅拌30分钟。减压蒸馏后，将体系溶于无水四氢呋喃(5ml)中，冰浴下逐滴加入来那度胺(518.5mg，2.0mmol)和DIEA(992ul，6.0mmol)的四氢呋喃(20ml)溶液，室温下搅拌过夜。反应完全后，减压蒸馏获得棕色固体，粗品用甲醇重结晶，得到化合物6，为橙色固体。
Figure PCTCN2019104300-appb-000018
(E)-4-((4-(2-氯乙氧基)苯基)二氮烯基)-N-(2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚-4-基)苯甲酰胺(6a)
1H NMR(300MHz,DMSO-d6)δ10.96(s,1H),10.48(s,1H),8.18(d,J＝8.2Hz,2H),7.96(dt,J＝8.9,4.2Hz,4H),7.76(d,J＝7.5Hz,1H),7.65–7.55(m,2H),7.26–7.14(m,2H),5.15(dd,J＝13.2,5.2Hz,1H),4.47(d,J＝2.6Hz,2H),4.40(t,J＝5.1Hz,2H),4.00(t,J＝5.1Hz,2H),2.99–2.81(m,1H),2.67–2.54(m,1H),2.45–2.27(m,1H),2.07–1.93(m,1H).
Figure PCTCN2019104300-appb-000019
(E)-4-((4-(2-氯丙氧基)苯基)二氮烯基)-N-(2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚-4-基)苯甲酰胺(6b)
1H NMR(300MHz,DMSO-d6)δ10.99(s,1H),10.51(s,1H),8.19(d,J＝8.2Hz,2H),7.97(dd,J＝8.4,5.8Hz,4H),7.77(d,J＝7.5Hz,1H),7.60(dt,J＝15.2,7.5Hz,2H),7.19(d,J＝8.6Hz,2H),5.17(dd,J＝13.2,5.0Hz,1H),4.54–4.38(m,2H),4.23(t,J＝6.0Hz,2H),3.83(t,J＝6.5Hz,2H),2.99–2.82(m,1H),2.64–2.54(m,1H),2.45–2.34(m,1H),2.23(p,J＝6.5Hz,2H),2.04–1.97(m,1H).
Figure PCTCN2019104300-appb-000020
(E)-4-((4-(2-氯丁氧基)苯基)二氮烯基)-N-(2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚-4-基)苯甲酰胺(6c)
1H NMR(300MHz,DMSO-d6)δ11.01(s,1H),10.53(s,1H),8.15(dd,J＝18.7,8.2Hz,2H),7.94(dd,J＝11.3,8.3Hz,4H),7.77(d,J＝7.4Hz,1H),7.60(dt,J＝14.9,7.4Hz,2H),7.16 (dd,J＝9.2,2.8Hz,2H),5.17(dd,J＝13.5,4.9Hz,1H),4.47(s,2H),4.15(s,2H),3.73(d,J＝6.5Hz,2H),2.99–2.85(m,1H),2.66–2.55(m,1H),2.48–2.33(m,1H),2.07–1.98(m,1H),1.96–1.79(m,4H).
Figure PCTCN2019104300-appb-000021
(E)-4-((4-(2-氯戊氧基)苯基)二氮烯基)-N-(2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚-4-基)苯甲酰胺(6d)
1H NMR(300MHz,DMSO-d6)δ10.90(s,1H),10.42(s,1H),8.09(d,J＝8.2Hz,2H),7.87(t,J＝7.9Hz,4H),7.67(d,J＝7.5Hz,1H),7.51(dt,J＝15.1,7.5Hz,2H),7.07(d,J＝8.5Hz,2H),5.07(dd,J＝13.1,5.2Hz,1H),4.43–4.33(m,2H),4.03(t,J＝6.3Hz,2H),3.59(t,J＝6.5Hz,2H),2.90–2.80(m,1H),2.62–2.48(m,1H),2.46–2.32(m,1H),1.99–1.87(m,1H),1.70(d,J＝9.7Hz,4H),1.47(t,J＝7.8Hz,2H).
Figure PCTCN2019104300-appb-000022
(E)-4-((4-(2-氯己氧基)苯基)二氮烯基)-N-(2-(2,6-二氧代哌啶-3-基)-1-氧代异吲哚-4-基)苯甲酰胺(6e)
1H NMR(300MHz,DMSO-d6)δ11.00(s,1H),10.52(s,1H),8.18(d,J＝8.3Hz,2H),7.95(t,J＝8.2Hz,4H),7.76(d,J＝7.4Hz,1H),7.60(dt,J＝15.0,7.4Hz,2H),7.15(d,J＝8.6Hz,2H),5.16(dd,J＝13.1,5.1Hz,1H),4.54–4.40(m,2H),4.10(t,J＝6.5Hz,2H),3.65(t,J＝6.6Hz,2H),2.96–2.84(m,1H),2.68–2.52(m,1H),2.46–2.33(m,1H),2.04–1.98(m,1H),1.88–1.62(m,4H),1.47(d,J＝7.1Hz,4H).
Figure PCTCN2019104300-appb-000023
N-(2-氯-6-甲基苯基)-2-(2-甲基-6-(哌嗪-1-基)嘧啶-4-基氨基)噻唑-5-甲酰胺(8)
将2-(6-氯-2-甲基嘧啶-4-基氨基)-N-(2-氯-6-甲基苯基)噻唑-5-甲酰胺，7(1.00g，2.54mmol)，哌嗪(2.19g，25.4mmol)、N，N-二异丙基乙胺(0.84mL，5.07mmol)溶于无水1,4-二氧六环(30ml) 中，回流12小时。减压蒸馏所得的油状物依次用水/甲醇、甲醇/醚洗涤，得灰白色固体，粗品用乙醚重结晶得到化合物8(0.82g，73％)。
1H NMR(300MHz,DMSO-d6)δ9.88(s,1H),8.21(s,1H),7.40(d,J＝7.3Hz,1H),7.26(d,J＝8.2Hz,2H),6.02(s,1H),3.44(s,4H),2.74(s,4H),2.40(d,J＝3.0Hz,3H),2.23(d,J＝2.9Hz,3H).
Figure PCTCN2019104300-appb-000024
向中间体6(0.11mmol)的丙酮(10ml)溶液中加入碘化钠(83mg，0.55mmol)，回流24小时，减压蒸馏得橘黄色固体。将固体溶于DMF(20ml)中，并依次加入化合物8(43mg，0.10mmol)和DIEA(96μL，0.57mmol)，80℃下搅拌16小时。将反应液冷却至室温，加入200mL水，有大量橙黄色固体析出，抽滤后粗品经TLC纯化(MeOH/DCM，1/50至1/25)，得到化合物9，橙色固体。
Figure PCTCN2019104300-appb-000025
(E)-N-(2-氯-6-甲基苯基)-2-((6-(4-(2-(4-((4-((2-(2,6-二氧代哌啶-3-基)-1-oxoisoindolin-4-基)氨甲酰基)苯基)二氮烯基)苯氧基)乙基)哌嗪-1-基)-2-甲基嘧啶-4-基)氨基)噻唑-5-甲酰胺(9a)
1H NMR(300MHz,DMSO-d 6)δ11.47(s,1H),10.99(s,1H),10.51(s,1H),9.87(s,1H),8.26–8.13(m,3H),8.06–7.85(m,4H),7.75(d,J＝7.4Hz,1H),7.68–7.46(m,2H),7.38(d,J＝7.4Hz,1H),7.32–7.15(m,4H),6.05(s,1H),5.15(dd,J＝13.2,5.2Hz,1H),4.43(d,J＝16.4Hz,2H),4.25(d,J＝5.1Hz,2H),3.59–3.46(m,4H),2.99–2.88(m,1H),2.77–2.67(m,1H),2.63–2.53(m,4H),2.40(s,3H),2.36–2.30(m,1H),2.22(s,3H),2.06–1.91(m,1H).MS(ESI):calcdfor C 48H 45ClN 12O 6S,952.30；m/z:[M] +＝953.3036
Figure PCTCN2019104300-appb-000026
(E)-N-(2-氯-6-甲基苯基)-2-((6-(4-(3-(4-((4-((2-(2,6-二氧代哌啶-3-基)-1-oxoisoindolin-4-基)氨甲酰基)苯基)二氮烯基)苯氧基)丙基)哌嗪-1-基)-2-甲基嘧啶-4-基)氨基)噻唑-5-甲酰胺(9b)
1H NMR(300MHz,DMSO-d 6)11.47(s,1H),10.99(s,1H),10.51(s,1H),9.87(s,1H),8.25–8.11(m,3H),7.95(dd,J＝8.5,5.9Hz,4H),7.75(d,J＝7.4Hz,1H),7.60(dd,J＝13.7,7.4Hz,2H),7.38(dd,J＝7.3,2.1Hz,1H),7.31–7.12(m,4H),6.04(s,1H),5.15(dd,J＝13.2,5.2Hz, 1H),4.46(s,2H),4.23–4.12(m,2H),3.59–3.46(m,4H),2.96–2.85(m,1H),2.63–2.60(m,1H),2.57–2.49(m,4H),2.39(s,3H),2.32–2.25(m,1H),2.22(s,3H),2.07–1.88(m,3H).MS(ESI):calcd for C 49H 47ClN 12O 6S,966.32；m/z[M]+:967.3325
Figure PCTCN2019104300-appb-000027
(E)-N-(2-氯-6-甲基苯基)-2-((6-(4-(4-(4-((4-((2-(2,6-二氧代哌啶-3-基)-1-oxoisoindolin-4-基)氨甲酰基)苯基)二氮烯基)苯氧基)丁基)哌嗪-1-基)-2-甲基嘧啶-4-基)氨基)噻唑-5-甲酰胺(9c)
1H NMR(300MHz,DMSO-d 6)δ11.41(s,1H),10.96(s,1H),10.44(d,J＝15.3Hz,1H),9.83(s,1H),8.30–8.09(m,3H),7.95(t,J＝7.4Hz,4H),7.80(dd,J＝18.2,7.5Hz,1H),7.58(h,J＝8.5,7.9Hz,3H),7.38(d,J＝7.4Hz,1H),7.25(d,J＝8.2Hz,2H),7.16(d,J＝8.8Hz,2H),6.05(d,J＝6.7Hz,1H),5.15(dd,J＝13.6,5.2Hz,1H),4.50(d,J＝17.5Hz,2H),4.13(d,J＝6.6Hz,2H),3.55–3.49(m,4H),3.05–2.79(m,1H),2.66–2.54(m,1H),2.44(s,3H),2.43–2.33(m,4H),2.32–2.26(m,1H),2.25–2.19(s,3H),2.10–1.95(m,1H),1.89–1.71(m,2H),1.63(t,J＝7.9Hz,2H).MS(ESI):calcd for C 50H 49ClN 12O 6S,980.33；m/z:[M] +＝981.33728
Figure PCTCN2019104300-appb-000028
(E)-N-(2-氯-6-甲基苯基)-2-((6-(4-(5-(4-((4-((2-(2,6-二氧代哌啶-3-基)-1-oxoisoindolin-4-基)氨甲酰基)苯基)二氮烯基)苯氧基)戊基)哌嗪-1-基)-2-甲基嘧啶-4-基)氨基)噻唑-5-甲酰胺(9d)
1H NMR(300MHz,DMSO-d 6)δ11.46(s,1H),10.99(s,1H),10.51(s,1H),9.86(s,1H),8.25–8.12(m,3H),7.95(t,J＝7.7Hz,4H),7.75(d,J＝7.4Hz,1H),7.60(dd,J＝13.6,7.2Hz,2H),7.38(d,J＝7.4Hz,1H),7.25(d,J＝7.9Hz,2H),7.15(d,J＝8.6Hz,2H),6.03(s,1H),5.15(dd,J＝12.2,5.2Hz,1H),4.50–4.37(m,2H),4.09(d,J＝6.7Hz,2H),3.60–3.41(m,4H),2.98–2.82(m,1H),2.64–2.53(m,1H),2.42(s,3H),2.41–2.34(m,4H),2.33–2.27(m,1H),2.22(s,3H),2.01–1.94(m,1H),1.85–1.70(m,2H),1.57–1.43(s,4H).MS(ESI):calcd for C 51H 51ClN 12O 6S 994.35；m/z:[M] +＝995.3535
Figure PCTCN2019104300-appb-000029
(E)-N-(2-氯-6-甲基苯基)-2-((6-(4-(6-(4-((4-((2-(2,6-二氧代哌啶-3-基)-1-oxoisoindolin-4-基)氨甲酰基)苯基)二氮烯基)苯氧基)己基)哌嗪-1-基)-2-甲基嘧啶-4-基)氨基)噻唑-5-甲酰胺 (9e)
1H NMR(300MHz,DMSO-d 6)δ11.39(s,1H),10.92(s,1H),10.41(s,1H),9.80(s,1H),8.25–8.02(m,3H),7.90(t,J＝8.1Hz,4H),7.73(p,J＝10.2,8.7Hz,1H),7.54(dt,J＝15.6,7.8Hz,2H),7.34(d,J＝7.3Hz,1H),7.20(d,J＝8.3Hz,2H),7.09(d,J＝8.6Hz,2H),6.00(s,1H),5.11(dd,J＝13.1,5.2Hz,1H),4.50–4.34(m,2H),4.04(t,J＝6.4Hz,2H),3.46(d,J＝6.7Hz,4H),2.96–2.78(m,1H),2.61–2.53(m,1H),2.41–2.31(m,4H),2.26(s,3H),2.21–2.11(m,4H),2.01–1.87(m,1H),1.79–1.64(m,2H),1.42(q,J＝7.1Hz,4H),1.34(d,J＝9.6Hz,2H).MS(ESI):calcd for C 52H 53ClN 12O 6S 1008.36；m/z:[M] +＝1009.36956
实施例2：效果实施例
最初，研究人员合成了2C化合物(图2A)，这是连接链最短(n＝1)的小分子，并使用BCR-ABL和CRBN阳性的K562细胞株，通过免疫印迹测试化合物在细胞中对ABL和BCR-ABL蛋白的降解情况。给药36小时后，WB结果显示化合物2C能够剂量依赖性地下调BCR-ABL蛋白的水平，在100nM浓度下的ABL蛋白和BCR-ABL融合蛋白水平的显着降低(图2B)。随后，研究人员尝试延长连接链(提高n值)。结果表明，随着接头延伸直至4个碳原子时，化合物的降解活性持续提高，但链长进一步延伸后活性逐渐降低。在这些PROTAC分子中，化合物4C降解BCR-ABL融合蛋白显示出最佳活性(图2C)。图2D为3C化合物对K562细胞株中ABL和BCR-ABL蛋白降解作用的量效关系；图2E为4C化合物对K562细胞株中ABL和BCR-ABL蛋白降解作用的量效关系；图2F为5C化合物对K562细胞株中ABL和BCR-ABL蛋白降解作用的量效关系；图2G为6C化合物对K562细胞株中ABL和BCR-ABL蛋白降解作用的量效关系。
上述试验表明，蛋白靶向降解嵌合分子2C、3C、4C、5C、6C均可不同程度地抑制BCR-ABL和/或CRBN阳性的白血病K562细胞中BCR-ABL和/或CRBN蛋白的表达，因而可以用于制备治疗BCR-ABL和/或CRBN阳性的白血病的药物。
实施例3：效果实施例
研究发现，化合物4C具有良好的光致异构化活性。化合物4C经200-275nM紫外光(UV-C)照射后，在345-425nm间trans-偶氮苯基团的特征吸收峰消失，这表明化合物由trans构型转变为cis构型(图3A)。随后，我们通过紫外-可见吸收光谱探究了化合物4C的光动力学特征。结果显示：在361nm是化合物4C-trans中偶氮基团的最大吸收(λmax)。经紫外照射后，361nm处的峰逐渐降低，这表明该化合物逐渐由trans构型转为cis构型。361nm处的吸光度-时间的曲线图表明：经紫外照射1小时，化合物基本完全转化为cis构型(图3B)。cis构型的化合物4C经白光照射，逐渐转化为trans构型(图3C)。此外，由于化合物4C是 T型光开关，cis构型在黑暗条件下经自发热弛豫转化为trans构型，在25℃时T1/2约为10小时。随后，我们测试了光敏开关的可逆性，结果表明：化合物4C在经紫外和白光轮流照射5次后依然相对稳定。
研究人员进一步评价了化合物4C的细胞活性。在抗K562细胞增殖活性测试中，化合物4C的半数抑制浓度(IC50)为68nM(图4A)；在细胞活力测试中，化合物4C的半数有效浓度(EC50)为28nM(图4B)；此外，化合物4C基本不影响非BCR-ABL依赖的肿瘤细胞系，如A549，HCT116，HEK293T和MCF-7乳腺癌(图4B)。由此可见，化合物4C对BCR-ABL依赖的K562细胞系有着良好的选择性。
其中，抗K562细胞增殖活性测试的操作方法如下：
在96孔板中配制100μL的K562细胞悬液及10μL不同浓度的待测化合物。将培养板放在培养箱孵育48小时(37℃，5％CO 2)。向每孔加入10μL CCK-8溶液。将培养板在培养箱内孵育1-4小时。用酶标仪测定在450nm处的吸光度。
细胞毒性活力(％)＝[A(加药)-A(空白)]/[A(0加药)-A(空白)]×100，其中：
A(加药)：具有细胞、CCK-8溶液和药物溶液的孔的吸光度
A(空白)：具有培养基和CCK-8溶液而没有细胞的孔的吸光度
A(0加药)：具有细胞、CCK-8溶液而没有药物溶液的孔的吸光度
其中，K562细胞活力测试的操作方法如下：
将50uL的K562，MCF-7，HCT116和A549的细胞悬液加入96孔板上孵育12小时，将10uL化合物加入孔中，孵育48小时后。按
Figure PCTCN2019104300-appb-000030
发光细胞活力测定试剂盒(Promega)操作。使用GraphPad Prism 6中的非线性回归分析数据。
为测试化合物4C对K562细胞中c-ABL和BCR-ABL蛋白的降解效果，研究人员进行了免疫印迹实验。时效实验显示：经250nM化合物4C孵育4小时后ABL明显降低，10小时后BCR-ABL和c-ABL蛋白均显着降解，32小时后ABL和BCR-ABL的达到最大降解，48小时后，K562细胞出现明显凋亡。为了排除化合物4C影响ABL基因产生假阳性的可能，研究人员在K562细胞中使用RT-qPCR研究了ABL基因的表达。结果如图7、图8所示。量效实验显示：与对照组相比，经不同浓度的化合物4C处理36小时后的K562细胞中，ABL基因的mRNA水平没有显着变化；时效实验显示，K562细胞经500nM的化合物4C孵育48小时中未观察到ABL基因的mRNA水平有显着降低。
免疫印迹实验的操作方法如下：
A.溶液和试剂
使用反渗透去离子水(RODI)或同等级别的水制备溶液。
1*PBS：加入50ml 20*PBS至950ml dH2O并混合。
1*TBS：加入100ml 10*TBS至900ml dH2O并混合。
1*电泳缓冲液：添加100ml 10*电泳缓冲液至900ml dH2O中并混合。
1*转移缓冲液：将100ml 10*转移缓冲液添加至100ml甲醇+800ml dH2O中，并混合。
1*TBST：将100ml 10X TBST添加至900ml dH2O中并混合。
封闭缓冲液：含5％w/v脱脂奶粉的1*TBST；
洗涤缓冲液：1*BST。
一抗稀释缓冲液：含5％脱脂奶粉的1*TBST；要制备20ml，添加1.0g脱脂奶粉至20ml1*TBST，然后充分混匀。
HRP偶联二抗：Anti-rabbit IgG、HRP-linked Antibody(#7074)。
检测试剂：SignalFire TM ECL Reagent(#6883)。
B.蛋白质印迹
制备样品：
给药后的K562细胞孵育24小时处理。
从培养物中吸出培养基；用1*PBS洗涤细胞；吸出。
加入弱效RIPA裂解液(100μl)来裂解细胞，裂解40min。
13000rpm、4℃、15min离心，取80μl上清液并加入20μl上样缓冲液，并在100℃下加热8分钟；放在冰上冷却。
上样10μL到10％的SDS-PAGE凝胶上。湿法转至PVDF膜上。
C.膜封闭和抗体孵育
I.膜封闭
将膜置于25ml封闭缓冲液中，在室温下封闭1小时。
用15ml TBST洗涤三次，每次5分钟。
II.一抗孵育
将膜和一抗(按照产品说明书中建议的适当稀释度和稀释液)置于10ml一抗稀释缓冲液中在4℃下孵育过夜并不时轻轻晃动。
用15ml TBST洗涤三次，每次5分钟。
使用10ml封闭缓冲液稀释Anti-rabbit IgG,HRP-linked Antibody(#7074，按1:2000的比例)和anti-biotin,HRP-linked Antibody(#7075，按1:1000-1:3000的比例)用以检测生物素化蛋白标准品。将膜与稀释液一起孵育，在室温下轻轻摇晃孵育1小时。
用15mlTBST洗涤三次，每次5分钟。
继续进行检测(D部分)。
D.蛋白质检测
使用说明：
在TBST中清洗与膜结合的HRP(Antibody Conjugate)三次，持续5分钟。
将显色液与膜一起孵育1分钟，倒掉多余溶液(膜将保持湿润)并曝光。
RT-qPCR实验的操作方法如下：
根据NCBI数据库中的相关基因信息，选择编码序列，委托金斯瑞生物科技有限公司设计合成引物，序列如下：
Figure PCTCN2019104300-appb-000031
收集于1.5mL离心管中的的K 562细胞重悬液短暂离心，吸去培养上清后加入适量Trizol试剂并反复吹打以裂解细胞，室温静置5min；向上述裂解液中加入0.2倍体积的氯仿，涡旋15s后，于室温静置3min；12000rpm、4℃离心15min，从离心机中小心取出离心管，吸取上层水相转移至新的离心管中；加入等体积的异丙醇，混匀后室温静置10min；12000rpm、4℃离心15min此时试管底部出现白色的RNA沉淀；小心弃去上清，加入1mL的75％乙醇(0.1％，DEPC水配制)，上下颠倒均匀；10min；12000rpm、4℃离心15min，为了RNA沉淀尽快在空气中干燥加入可500μL无水乙醇除水；待白色状核酸刚好消失时，加入适量的0.1％DEPC水重悬，混匀后，用分光光度计检测所提取RNA样品的纯度和浓度，RNA溶液的A260/A280的比值即为RNA纯度，比值范围1.8到2.1。
按下表配置cDNA，轻弹管底将溶液混合，6000rpm短暂离心。混合液在加入逆转录酶MMLV之前先70℃干浴3分钟，取出后立即冰水浴至管内外温度一致，然后加逆转录酶0.5ul，37℃水浴60分钟。取出后立即95℃干浴3分钟，得到逆转录终溶液即为cDNA溶液，保存于-80℃待用。
取0.2ml薄壁PCR管,分别编号。向各管中加入2×qPCR TaqMix12.5ul,10uM各基因正反向引物混合物0.5ul,对应的cDNA各1ul。一管中不加模板用作阴性对照。各管补加水至25ul。混匀,置于SLAN荧光定量PCR仪中。95℃5min预变性后,95℃15s→65℃35s(荧光检测),40cycles。
Figure PCTCN2019104300-appb-000032
Figure PCTCN2019104300-appb-000033
接下来，我们测试了化合物4C的不同构型对ABL和BCR-ABL蛋白降解活性的差异。免疫印迹的结果表明：trans构型的4C化合物在25nM浓度下能够轻微降解BCR-ABL融合蛋白，500nM浓度下超过80％的BCR-ABL和几乎所有ABL蛋白被降解(图5A)。在相同条件下，cis构型的4C化合物在250nM浓度下对BCR-ABL蛋白没有明显降解(图5C)。时效实验显示：trans构型的化合物4C在250nM浓度下，4小时后观察到BCR-ABL略微减少，10小时后BCR-ABL融合蛋白明显减少，32小时后超过90％BCR-ABL融合蛋白被降解(图5B)；相同条件下的cis构型化合物4C在孵育32小时后没有观察到BCR-ABL的显着减少(图5D)。以上结果均证明化合物4C的trans和cis构型在降解活性上有很大差异，仅有trans构型能有效降解BCR-ABL蛋白。免疫印迹实验的操作方法同前述。
为模拟光控过程，研究人员用化合物4C-trans处理K562细胞24小时，然后将这些细胞移至新鲜培养基中并分成2组：一组置于暗室中(VIS组)，另一组分别在孵育0、4、8、12、16、24后小时经紫外照射，以此模拟光致异构化过程(UV组)。结果显示：黑暗组中，BCR-ABL融合蛋白维持在低水平，ABL几乎消失(图6-VIS)，而在UV组中，ABL和BCR-ABL水平随时间推移而增加(图6-UV)。这些结果均证明：经紫外照射变构后的4C化合物失去了降解活性，通过紫外照射，我们可以随时终止PROTAC降解过程。
模拟光控的具体操作方法如下：
将终浓度100nM化合物4C-trans加入K562细胞中，37℃孵育24小时；洗去培养基并用1*PBS洗涤2次，后将细胞转移至新鲜的1640培养基中(10％FBS，1*谷氨酰胺)培养，并分成两组：一组置于暗室中，另一组每4小时用UV-C灯照射30min；分别在转移并孵育0、4、8、16、24小时后收集细胞，细胞后处理与免疫印迹相同。
上述实施例的作用在于具体介绍本发明的实质性内容，但本领域技术人员应当知道，不应将本发明的保护范围局限于该具体实施例。

Claims (5)

  1. 一种蛋白靶向降解嵌合分子，其特征在于，化学结构式如下：
    Figure PCTCN2019104300-appb-100001
    其中，n为1～5任一自然数。
  2. 根据权利要求1所述的蛋白靶向降解嵌合分子，其特征在于：n＝3。
  3. 权利要求1所述蛋白靶向降解嵌合分子的合成方法，其特征在于，合成路线如下：
    Figure PCTCN2019104300-appb-100002
    其中，n为1～5中任一自然数。
  4. 权利要求1所述的蛋白靶向降解嵌合分子在制备治疗BCR-ABL和/或CRBN阳性的白血病的药物中的应用。
  5. 权利要求2所述的蛋白靶向降解嵌合分子在制备光照调控降解BCR-ABL和/或CRBN蛋白的试剂或药物方面的应用。
PCT/CN2019/104300 2019-01-26 2019-09-04 一种蛋白靶向降解嵌合分子、制备方法及应用 Ceased WO2020151229A1 (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US15/734,960 US11504385B2 (en) 2019-01-26 2019-09-04 Proteolysis targeting chimeric molecule, preparation method, and application

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
CN201910076670.4A CN109761970B (zh) 2019-01-26 2019-01-26 一种蛋白靶向降解嵌合分子、制备方法及应用
CN201910076670.4 2019-01-26

Publications (1)

Publication Number Publication Date
WO2020151229A1 true WO2020151229A1 (zh) 2020-07-30

Family

ID=66455414

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/CN2019/104300 Ceased WO2020151229A1 (zh) 2019-01-26 2019-09-04 一种蛋白靶向降解嵌合分子、制备方法及应用

Country Status (3)

Country Link
US (1) US11504385B2 (zh)
CN (1) CN109761970B (zh)
WO (1) WO2020151229A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN109761970B (zh) * 2019-01-26 2020-06-09 中国药科大学 一种蛋白靶向降解嵌合分子、制备方法及应用
CN114044775B (zh) * 2021-08-30 2023-04-07 杭州医学院 一种靶向泛素化诱导bcr-abl蛋白降解的化合物及其应用
CN115109047B (zh) * 2021-09-08 2024-02-20 中国科学院化学研究所 一种基于protac设计的铁死亡诱导剂
CN114349739A (zh) * 2021-12-14 2022-04-15 杭州医学院 一种降解微管蛋白的偶氮类化合物及其合成方法和应用
CN115991880B (zh) * 2022-12-08 2024-03-19 中国药科大学 一种树状大分子pamam-g5-tco及其制备方法与应用
CN121443600A (zh) 2023-05-26 2026-01-30 北京盛诺基医药科技股份有限公司 一种靶向雌激素受体的protac化合物及其制备方法和用途

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062220A1 (en) * 2002-01-23 2003-07-31 Novartis Ag N-oxyde of n-phenyl-2-pyrimidine-amine derivatives
CN107382862A (zh) * 2017-07-17 2017-11-24 大连理工大学 硫/氧代萘酰亚胺类化合物及其应用
CN107540608A (zh) * 2017-07-17 2018-01-05 大连理工大学 4‑取代萘酰亚胺类化合物及其应用
CN107922927A (zh) * 2015-06-19 2018-04-17 学校法人东京理科大学 蛋白质分解诱导标签及其用途
CN108610295A (zh) * 2018-04-04 2018-10-02 大连医科大学附属第医院 嘧啶类化合物，组合物及其在治疗淋巴瘤白血病中的用途
CN109761970A (zh) * 2019-01-26 2019-05-17 中国药科大学 一种蛋白靶向降解嵌合分子、制备方法及应用

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003062220A1 (en) * 2002-01-23 2003-07-31 Novartis Ag N-oxyde of n-phenyl-2-pyrimidine-amine derivatives
CN107922927A (zh) * 2015-06-19 2018-04-17 学校法人东京理科大学 蛋白质分解诱导标签及其用途
CN107382862A (zh) * 2017-07-17 2017-11-24 大连理工大学 硫/氧代萘酰亚胺类化合物及其应用
CN107540608A (zh) * 2017-07-17 2018-01-05 大连理工大学 4‑取代萘酰亚胺类化合物及其应用
CN108610295A (zh) * 2018-04-04 2018-10-02 大连医科大学附属第医院 嘧啶类化合物，组合物及其在治疗淋巴瘤白血病中的用途
CN109761970A (zh) * 2019-01-26 2019-05-17 中国药科大学 一种蛋白靶向降解嵌合分子、制备方法及应用

Also Published As

Publication number Publication date
CN109761970B (zh) 2020-06-09
US11504385B2 (en) 2022-11-22
CN109761970A (zh) 2019-05-17
US20210338695A1 (en) 2021-11-04

Similar Documents

Publication Publication Date Title
WO2020151229A1 (zh) 一种蛋白靶向降解嵌合分子、制备方法及应用
CN114516867B (zh) 一类含氧五元杂环化合物、合成方法、药物组合物及用途
Liu et al. Design, synthesis and biological evaluation of novel thieno [3, 2-d] pyrimidine derivatives possessing diaryl semicarbazone scaffolds as potent antitumor agents
Xu et al. A fluorescent sensor for discrimination of HSA from BSA through selectivity evolution
Ibrahim et al. Synthesis and biological evaluation of some novel thiobenzimidazole derivatives as anti-renal cancer agents through inhibition of c-MET kinase
Zhang et al. Synthesis and anticancer activities of 5, 6, 7-trimethoxy-N-phenyl (ethyl)-4-aminoquinazoline derivatives
CN107973787A (zh) 一种香豆素衍生物dmac及其制备方法和应用
Tan et al. Synthesis of novel 4-substituted isatin Schiff base derivatives as potential autophagy inducers and evaluation of their antitumour activity
CN116640123B (zh) 诱导hk2蛋白降解的双功能分子化合物及其合成和用途
CN108251104B (zh) 一种取代吲哚-2-羧酸类Bcl-2小分子荧光探针及其应用
Zhou et al. Small molecules inhibit STAT3 activation, autophagy, and cancer cell anchorage-independent growth
WO2019114741A1 (zh) 作为Akt抑制剂的盐型及其晶型
Wang et al. Development of a fluorescent ligand that specifically binds to the c-MYC G-quadruplex by migrating the benzene group on a carbazole-benzothiazolium scaffold
CN104946244B (zh) 检测o2·‑的荧光分子探针、其合成方法和应用
CN109316479B (zh) 一种萘酚类化合物的制备及其在癌症治疗方面的应用
CN111138373B (zh) 一种用于检测一氧化氮浓度的荧光探针及其合成方法和应用
EP3027594A1 (en) 2-benzoylaminobenzamide derivatives as bcl-3 inhibitors
CN113087682A (zh) 苯并噻唑衍生物荧光探针、制备方法、中间体及应用
CN115677608B (zh) 苯并异噁唑-3-甲酰胺类化合物及其合成和应用
CN110590681A (zh) 一种新型喹唑啉酮类化合物及其制备方法和应用
WO2018214958A1 (zh) Ido1抑制剂的晶型及其制备方法
CN104817535A (zh) 一种喹啉酮衍生物及其合成方法及应用
CN112209888B (zh) 一种4-芳巯基喹唑啉类化合物、制备方法和医药用途
CN111247137A (zh) 一种嘧啶类化合物、其制备方法及其医药用途
CN102796094B (zh) 二卤荧光素衍生物及其用途

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19911682

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19911682

Country of ref document: EP

Kind code of ref document: A1